Eddie J. Sullivan

Eddie J. Sullivan, PhD

Eddie J. Sullivan, PhD, is our co-founder and has served as our president and Chief Executive Officer since 2014. Dr. Sullivan has served in biopharma leadership positions for more than 25 years. Prior to joining SAB, he was the CEO of Hematech, a subsidiary of Kyowa Hakko Kirin, where he led initiatives to develop infectious disease, cancer, and autoimmune immunotherapies. In addition to raising over $250 million in capital to develop biopharmaceutical platform technologies, he has led several successful mergers and acquisitions. A recognized thought leader in antibodies and transgenic animals, Dr. Sullivan serves on the board of directors for the Biotechnology Innovation Organization (BIO), has served on its executive committee and founded the state affiliate of BIO, South Dakota Biotech. Dr. Sullivan was governor-appointed to South Dakota’s Research Commercialization Council and is Chairman of the state’s National Science Foundation-EPSCoR (Established Program to Stimulate Competitive Research) committee. Dr. Sullivan earned two Ph.D.’s in Health Science Administration and Reproductive Physiology from Kennedy Western University and Utah State University, respectively. In addition, he holds a M.S. in Reproductive Physiology and Molecular Biology from Brigham Young University and a B.S. in Animal Health Sciences from the University of Arizona.